# Once-a-day Immunosuppression(CISECON\_a\_day)

Study · id `cardio:ct-nct01964014` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01964014](<https://clinicaltrials.gov/study/NCT01964014>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01964014

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 160 participants.

## Technical summary

Registry record NCT01964014. Allocation not applicable; no masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2015-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 160 participants (enrolled count; ClinicalTrials.gov record NCT01964014, source copy `cardio:ctgov-nct01964014-2016-07-21`, retrieved 2026-10-26)
- Start date: 2013-10 (registry gives no type) (ClinicalTrials.gov record NCT01964014, source copy `cardio:ctgov-nct01964014-2016-07-21`, retrieved 2026-10-26)
- Primary completion: 2015-10 (actual) (ClinicalTrials.gov record NCT01964014, source copy `cardio:ctgov-nct01964014-2016-07-21`, retrieved 2026-10-26)
- Completion: 2015-10 (actual) (ClinicalTrials.gov record NCT01964014, source copy `cardio:ctgov-nct01964014-2016-07-21`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01964014, source copy `cardio:ctgov-nct01964014-2016-07-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01964014-2016-07-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Once-a-day Immunosuppression(CISECON\_a\_day)
- Acronym: CISECON
- Condition: Chronic Renal Disease
- Intervention (Drug): advagrf
- Lead sponsor: Ajou University School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Ajou University School of Medicine (`cardio:org-ajou-university-school-of-medicine`)

## Provenance

Content hash: e2da817e28f7479a411b3594474a43a9aa8092639a15965aaa72641c6dbea76d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
